Warning bells for the NHS are ringing again after the latest performance data showed the highest number of emergency admissions since records began and more patients than ever before waiting more than four hours for treatment.
News
UCB and PharmaMar breach ABPI Code of Practice
UCB and PharmaMar have been named in advertisements for breaching the Association of the British Pharmaceutical Industry’s Code of Practice.
UK’s Enterprise Therapeutics raises £29m
Brighton, UK-based Enterprise Therapeutics has raised £29 million to help it advance its experimental therapies for respiratory diseases.
GSK hands rare disease gene therapies over to Orchard
Orchard Therapeutics has snapped up GlaxoSmithKline’s portfolio of approved and investigational rare disease gene therapies.
Pfizer pulls plug on Inlyta trial
Pfizer is terminating a late-stage trial assessing Inlyta in patients at risk of kidney cancer recurrence after an interim analysis showed that it was highly unlikely the drug would offer any benefit in this setting.
US delay for AbbVie/Neurocrine’s uterine pain drug
The US Food and Drug Administration has extended its review of AbbVie and Neurocrine’s experimental uterine pain drug elagolix by three months.
Final guidance from NICE on Merck, Pfizer’s Bavencio
The National Institute for Health and Care Excellence has now published final guidelines endorsing Merck and Pfizer’s Bavencio as an option for patients with Merkel cell carcinoma (MCC).
Novartis’ Afinitor Disperz wins new TSC-related approval
Novartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two years and above with tuberous sclerosis complex (TSC)-associated partial-onset seizures.
Alexion to buy Wilson for $855m
Alexion Pharmaceuticals has offered to buy Wilson Therapeutics in a deal worth around $855 million.
vTv reports Alzheimer’s candidate failure
It is looking likely that another late-stage candidate for Alzheimer’s disease will fail to make it past Phase III trials, with vTv Therapeutics’ experimental therapy the latest in a long line to miss its targets.
NICE no for Roche’s Alecensa
The National Institute for Health and Care Excellence has turned down NHS funding for Roche’s Alecensa as a first-line treatment for lung cancer.
EU regulators expand reach of Sobi’s Kineret
European regulators have expanded the scope of Sobi’s Kineret to include the treatment of Still’s disease, a rare, systemic, multi-organ, auto-inflammatory disorder that affects around 25,000 children and adults in the EU.
AZ buys Ionis’ NASH candidate
AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million
Theresa May unveils £75m prostate cancer research fund
Prime Minister Theresa May has announced an investment of £75 million into research targeting earlier diagnosis and better treatment for men with prostate cancer.
SMC endorses five new therapies for NHS Scotland
Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions.
